Harbour BioMed Overview
- Year Founded
-
2016
- Status
-
Public
- Employees
-
183
- Stock Symbol
-
02142
- Investments
-
3
- Share Price
-
$0.99
- (As of Thursday Closing)
Harbour BioMed General Information
Description
HBM Holdings Ltd is a clinical-stage biopharmaceutical company engaged in the discovery and development of differentiated antibody therapeutics in immunology and oncology disease areas. Its products under development are Batoclimab, for the treatment of a wide spectrum of autoimmune diseases; Tanfanercept, for the treatment of moderate-to-severe dry eye disease (DED); HBM4003; HBM9378, to prevent and treat COVID-19, the pandemic respiratory disease caused by the SARS-CoV-2 virus; HBM7008; and others. Its geographical segments are Mainland China, United States, Europe, and others. The majority of the revenue for the firm is generated from the United States.
Contact Information
Website
www.harbourbiomed.comCorporate Office
- The Harbourfront 18 Tak Fung Street
- Unit 1607 A, Floor 16, Office Tower One
- Kowloon, 348
- Hong Kong
Corporate Office
- The Harbourfront 18 Tak Fung Street
- Unit 1607 A, Floor 16, Office Tower One
- Kowloon, 348
- Hong Kong
Harbour BioMed Stock Performance
As of 19-Jun-2025, Harbour BioMed’s stock price is $0.99. Its current market cap is $788M with 794M shares.
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.99 | $1.05 | $0.14 - $1.29 | $788M | 794M | 11.7M |
Harbour BioMed Financials Summary
As of 31-Dec-2024, Harbour BioMed has a trailing 12-month revenue of $38.1M.
|
In Thousands, USD |
TTM 31-Dec-2024 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 |
|---|---|---|---|---|
| EV | 59,718 | 59,718 | 85,752 | 126,726 |
| Revenue | 38,100 | 38,100 | 89,502 | 40,659 |
| EBITDA | 3,346 | 3,346 | 25,561 | (129,864) |
| Net Income | 2,778 | 2,778 | 22,797 | (137,222) |
| Total Assets | 215,014 | 215,014 | 228,480 | 232,123 |
| Total Debt | 61,339 | 61,339 | 66,012 | 90,929 |
Harbour BioMed Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Harbour BioMed Comparisons
Industry
Financing
Details
Harbour BioMed Competitors (97)
One of Harbour BioMed’s 97 competitors is Brii Biosciences, a Formerly VC-backed company based in Beijing, China.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Brii Biosciences | Formerly VC-backed | Beijing, China | ||||
| CARsgen Therapeutics | Formerly VC-backed | Shanghai, China | ||||
| Zai Lab | Formerly VC-backed | Shanghai, China | ||||
| Inovio Pharmaceuticals | Corporation | Plymouth Meeting, PA | ||||
| Clover Biopharmaceuticals | Formerly VC-backed | Shanghai, China |
Harbour BioMed Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Harbour BioMed Patents
Harbour BioMed Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2023372213-A1 | Bcma vh-only cars | Pending | 04-Nov-2022 | ||
| EP-4526347-A1 | Anti-cd200r1 antibodies | Pending | 19-May-2022 | ||
| EP-4506366-A1 | Antigen-binding protein targeting pd-l1 and cd40, preparation therefor, and use thereof | Pending | 02-Apr-2022 | ||
| EP-4506364-A1 | Antigen binding protein targeting cd40, and preparation therefor and use thereof | Pending | 02-Apr-2022 | ||
| JP-2025511356-A | Antigen-binding proteins targeting pd-l1 and cd40 and their production and application | Pending | 02-Apr-2022 | C07K16/2878 |
Harbour BioMed Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Harbour BioMed Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Harbour BioMed Investments & Acquisitions (3)
Harbour BioMed’s most recent deal was a Early Stage VC with Windward Bio for . The deal was made on 10-Jan-2025.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Windward Bio | 10-Jan-2025 | Early Stage VC | Drug Discovery | ||
| Harbour Antibodies | 19-Dec-2016 | Merger/Acquisition | Drug Discovery | ||
| HBM Alpha | Joint Venture | Biotechnology |
Harbour BioMed Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Harbour Antibodies | 2006 |
Harbour BioMed FAQs
-
When was Harbour BioMed founded?
Harbour BioMed was founded in 2016.
-
Where is Harbour BioMed headquartered?
Harbour BioMed is headquartered in Kowloon, Hong Kong.
-
What is the size of Harbour BioMed?
Harbour BioMed has 183 total employees.
-
What industry is Harbour BioMed in?
Harbour BioMed’s primary industry is Drug Discovery.
-
Is Harbour BioMed a private or public company?
Harbour BioMed is a Public company.
-
What is Harbour BioMed’s stock symbol?
The ticker symbol for Harbour BioMed is 02142.
-
What is the current stock price of Harbour BioMed?
As of 19-Jun-2025 the stock price of Harbour BioMed is $0.99.
-
What is the current market cap of Harbour BioMed?
The current market capitalization of Harbour BioMed is $788M.
-
What is Harbour BioMed’s current revenue?
The trailing twelve month revenue for Harbour BioMed is $38.1M.
-
Who are Harbour BioMed’s competitors?
Brii Biosciences, CARsgen Therapeutics, Zai Lab, Inovio Pharmaceuticals, and Clover Biopharmaceuticals are some of the 97 competitors of Harbour BioMed.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
